Literature DB >> 24696192

Prediction of Hepatocellular Carcinoma Recurrence in Patients With Low Hepatitis B Virus DNA Levels and High Preoperative Hepatitis B Surface Antigen Levels.

Gang Huang1, Wan Yee Lau2, Wei-ping Zhou1, Feng Shen1, Ze-ya Pan1, Sheng-xian Yuan1, Meng-chao Wu1.   

Abstract

IMPORTANCE: In patients with low viral loads, high levels of hepatitis B surface antigen (HBsAg) have been shown to predict development of hepatocellular carcinoma (HCC). Whether high levels of HBsAg increase the risk for HCC recurrence after hepatic resection remains unknown.
OBJECTIVE: To investigate the association between levels of HBsAg and the risk for tumor recurrence after curative resection in HCC patients with low levels of hepatitis B virus (HBV) DNA. DESIGN, SETTING, AND PARTICIPANTS: We performed a retrospective analysis of the clinical data of 1062 patients with low HBV DNA levels (<200 IU/mL) who underwent partial hepatectomy for HCC. In particular, we investigated the association between levels of HBsAg and recurrence of HCC. EXPOSURE: Partial hepatectomy for HCC. MAIN OUTCOMES AND MEASURES: The risk for first tumor recurrence between patients with high and low HBsAg levels. We calculated cumulative incidences and hazard ratios after adjusting for competing mortality.
RESULTS: The risk for tumor recurrence increased with HBsAg levels of 1000 IU/mL or greater. When we compared the groups with low (<1000 IU/mL) and high (≥1000 IU/mL) HBsAg levels, the 5-year disease-free survival rate (46.1% vs 34.1% [P = .002]) and the overall survival rate (57.5% vs 48.8% [P = .004]) were better in the group with low HBsAg levels. On multivariate analysis, hepatitis B e antigen seropositivity, HBsAg level of 1000 IU/mL or greater, tumor size of greater than 5 cm, blood transfusion, surgical margin of less than 1.0 cm, the presence of satellite nodules, and the presence of portal vein tumor thrombus were independent risk factors for HCC recurrence. When compared with hepatitis B e antigen status, HBsAg level better predicted recurrence of HCC. CONCLUSIONS AND RELEVANCE: A preoperative HBsAg level of 1000 IU/mL or greater is an independent risk factor for HCC recurrence in patients with low HBV DNA levels.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24696192     DOI: 10.1001/jamasurg.2013.4648

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  20 in total

1.  Impact of Preoperative Hepatitis B Virus Levels on Prognosis After Primary and Repeat Hepatectomies for Hepatocellular Carcinoma Patients-a Retrospective Study.

Authors:  Pin-Gao Yan; Ruo-Yu Wang; Jin Zhang; Wen-Ming Cong; Hui Dong; Hong-Yu Yu; Wan Yee Lau; Meng-Chao Wu; Wei-Ping Zhou
Journal:  J Gastrointest Surg       Date:  2018-01-08       Impact factor: 3.452

2.  No impact of perioperative blood transfusion on prognosis after curative resection for hepatocellular carcinoma: a propensity score matching analysis.

Authors:  T Peng; G Zhao; L Wang; J Wu; H Cui; Y Liang; R Zhou; Z Liu; Q Wang
Journal:  Clin Transl Oncol       Date:  2017-10-27       Impact factor: 3.405

3.  Adjuvant antiviral therapy for the prevention of hepatocellular carcinoma recurrence after liver resection: indicated for all patients with chronic hepatitis B?

Authors:  Clifford Akateh; Timothy M Pawlik; Jordan M Cloyd
Journal:  Ann Transl Med       Date:  2018-10

4.  Level of hepatitis B surface antigen might serve as a new marker to predict hepatocellular carcinoma recurrence following curative resection in patients with low viral load.

Authors:  Hua-Bang Zhou; Qiao-Mei Li; Zheng-Rong Zhong; Jing-Yi Hu; Xiao-Lan Jiang; Hao Wang; Hui Wang; Bing Yang; He-Ping Hu
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

5.  Safety and Efficacy of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma (3-5 cm): a Propensity Score Matching Cohort Study.

Authors:  Qing-Wang Ye; Shu-Jie Pang; Ning Yang; Hai-Bin Zhang; Yong Fu; Bin Lin; Guang-Shun Yang
Journal:  J Gastrointest Surg       Date:  2019-06-13       Impact factor: 3.452

6.  Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection.

Authors:  Ming-Chao Tsai; Chih-Chi Wang; Wei-Chen Lee; Chih-Che Lin; Kuo-Chin Chang; Chien-Hung Chen; Chao-Hung Hung; Ming-Tsung Lin; Chang-Chun Hsiao; Chao-Long Chen; Rong-Nan Chien; Tsung-Hui Hu
Journal:  Liver Cancer       Date:  2021-09-21       Impact factor: 11.740

7.  The Relationship Between Collagen Proportionate Area and Hepatitis B Surface Antigen Levels in E Antigen Positive Hepatitis B Cirrhosis.

Authors:  Qiangwei Shi; Rui Yu; Qian Sun; Chunfeng Wang; Jianning Yao; Lianfeng Zhang
Journal:  Turk J Gastroenterol       Date:  2022-01       Impact factor: 1.555

8.  Cholecystectomy is associated with higher risk of early recurrence and poorer survival after curative resection for early stage hepatocellular carcinoma.

Authors:  Tao Li; Shu-Kang Wang; Xu-Ting Zhi; Jian Zhou; Zhao-Ru Dong; Zong-Li Zhang; Hui-Chuan Sun; Qing-Hai Ye; Jia Fan
Journal:  Sci Rep       Date:  2016-06-20       Impact factor: 4.379

9.  Perioperative Transfusion is Related to the Length of Hospital Stays in Primary Liver Cancer Patients.

Authors:  Qi Qi; Xuemeng Qian; Xinfang Zhu; Jiajing Cai; Rong Xia; Qi Zhang
Journal:  Cancer Manag Res       Date:  2021-06-21       Impact factor: 3.989

10.  Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection.

Authors:  Jian-Lin Chen; Xiao-Jun Lin; Qian Zhou; Ming Shi; Sheng-Ping Li; Xiang-Ming Lao
Journal:  Chin J Cancer       Date:  2016-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.